Therefore, SLC7A11-AS1 attenuated β-TrCP-mediated degradation of NRF2, reduced ROS levels, and increased cancer stemness, which promoted gemcitabine resistance in PDAC (35). The gene discussed is SLC7A11; the disease is cancer.